DTIL התחייבויות לטווח ארוך Precision BioSciences

This chart of Precision BioSciences (DTIL) stock quotes reflects the performance of a company with a metric of 0.02. The business relies on its proprietary ARCUS system, which creates a protective barrier against patent conflicts. Ownership of this tool guarantees stable royalties from global pharma behemoths. The implementation of automated precision analysis stations is currently significantly reducing the timelines for preliminary research on new drugs.

Long-term debt aggregates all obligations with maturities exceeding twelve months, allowing for an assessment of capital structure stability and default risk in the absence of liquidity. When analyzing the current level of the firm's long-term borrowings, it is essential to consider the negative cash flow of Precision BioSciences (DTIL) resulting from ARCUS development costs, which makes credit load control a critical survival factor for the company.